Targeting PHGDH upregulation reduces glutathione levels and re-sensitizes resistant NRAS mutant melanoma to MEK inhibition

Melanomas frequently harbor activating NRAS mutations leading to activation of MEK-ERK1/2 signaling; however, clinical efficacy of inhibitors to this pathway are limited by resistance. Tumors re-wire metabolic pathways in response to stress signals such as targeted inhibitors and drug resistance, bu...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Invest Dermatol
Auteurs principaux: Nguyen, Mai Q., Teh, Jessica L.F., Purwin, Timothy J., Chervoneva, Inna, Davies, Michael A., Nathanson, Katherine L., Cheng, Phil F., Levesque, Mitchell P., Dummer, Reinhard, Aplin, Andrew E.
Format: Artigo
Langue:Inglês
Publié: 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7606255/
https://ncbi.nlm.nih.gov/pubmed/32389536
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jid.2020.02.047
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires